Fig. 2 | British Journal of Cancer

Fig. 2

From: Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer

Fig. 2

a Pictures of representative tumours after 1 week of treatment (upper), H&E staining (middle), and Ki67 staining (lower). All mice treated with PLX4720 singly or in combination had reduced cellular proliferation. b PD-L1 surface expression increased in all mice treated with anti-PD-1 singly or in combination. c None of the treatments led to changes in surface MHC-I expression. N = 4 mice per group, repeated twice

Back to article page